

NextCell Pharma presents historical quarterly figures

At the Extraordinary General Meeting of NextCell Pharma AB (publ) ("NextCell" or the "Company") held on 21 August 2025, it was resolved that the Company shall change its financial year from a broken financial year September–August to a calendar year January–December. The Company's first full financial year in accordance with the calendar year will be 2026. To facilitate historical comparisons and enhance transparency for future reports that will follow the calendar year structure, the Company is today publishing financial information for the five most recent comparative quarters.

During the extended financial year 2024/2025, the following interim reports were published:

- Q1: September–November 2024, published 30 January 2025
- Q2: December 2024–February 2025 (accumulated September 2024–February 2025), published 25 April 2025
- Q3: February 2025–April 2025 (accumulated September 2024–April 2025), published 24 July 2025
- Q4: May 2025–August 2025 (accumulated September 2024–August 2025), published 30 October 2025
- Year-end report: October 2025–December 2025 (accumulated September 2024–December 2025), published 26 February 2026

The Year-end Report 2025 for the period September 2024–December 2025 was NextCell Pharma's first interim report prepared in accordance with the calendar year structure. The quarter reported was October–December 2025 (accumulated September 2024–December 2025). The Q1 2026 report for the period January–March 2026 will be NextCell Pharma's first interim report under the ordinary calendar year structure and will be published on 28th of May 2026.

The summary of the comparison quarters contains no new information, other than a new quarterly breakdown based on the structure of the calendar year, derived from previously published data.

The report is available on the company's [website](#).

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Eric Gustafsson, CFO
Tel: 08-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market. RedEye Sweden AB is the company's Certified Adviser.

Om NextCell Pharma AB:

NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell's subsidiaries include Cellaviva, Scandinavia's largest private stem cell bank, and QVance, the Nordic region's first dedicated provider of quality services for developers of advanced therapies.